海正药业：11月19日召开董事会会议

Group 1 - The core point of the article is that Haizheng Pharmaceutical announced the establishment of a wholly-owned subsidiary in Jiaojiang to advance its pet prescription food project [1] - The company's revenue composition for the year 2024 is as follows: pharmaceutical production accounts for 58.46%, drug sales for 39.29%, other industries for 1.94%, other businesses for 0.23%, and CMO/CDMO/CRO business for 0.08% [1] - As of the report, Haizheng Pharmaceutical has a market capitalization of 12.8 billion yuan [1]